Cite
Mann JE, Hoesli R, Michmerhuizen NL, et al. Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer. 2017;8(3):332-344doi: 10.7150/jca.17547.
Mann, J. E., Hoesli, R., Michmerhuizen, N. L., Devenport, S. N., Ludwig, M. L., Vandenberg, T. R., Matovina, C., Jawad, N., Mierzwa, M., Shuman, A. G., Spector, M. E., & Brenner, J. C. (2017). Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. Journal of Cancer, 8(3), 332-344. https://doi.org/10.7150/jca.17547
Mann, J E, et al. "Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC." Journal of Cancer vol. 8,3 (2017): 332-344. doi: https://doi.org/10.7150/jca.17547
Mann JE, Hoesli R, Michmerhuizen NL, Devenport SN, Ludwig ML, Vandenberg TR, Matovina C, Jawad N, Mierzwa M, Shuman AG, Spector ME, Brenner JC. Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer. 2017 Feb 09;8(3):332-344. doi: 10.7150/jca.17547. eCollection 2017. PMID: 28261333; PMCID: PMC5332883.
Copy
Download .nbib